(Q30664269)

26 June 2017

1 reference

Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data (English)

1 reference

26 June 2017

1 reference

Zhihong O'Brien

1

1 reference

26 June 2017

Mehran Fallah Moghaddam

series ordinal

2

1 reference

26 June 2017

language of work or name

English

0 references

publication date

31 August 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

26 June 2017

published in

1 reference

26 June 2017

volume

9

1 reference

26 June 2017

issue

12

1 reference

26 June 2017

page(s)

1597-1612

1 reference

Oncogenic kinase signalling

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Structural organization of the bcr gene and its role in the Ph' translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Protein tyrosine kinases associated with human malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Targeting cancer with small-molecular-weight kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Molecular properties that influence the oral bioavailability of drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Role of phosphatidylserine binding in tissue distribution of amine-containing basic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

High-throughput pKa screening and prediction amenable for ADME profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Interaction of imatinib mesilate with human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.834046

10.1517/17425255.2013.834046

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference